54
Participants
Start Date
February 24, 2015
Primary Completion Date
December 24, 2019
Study Completion Date
December 24, 2019
Placebo
Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
Valganciclovir
Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
Texas Medical Center - Texas Children's Hospital, Houston
Children's of Alabama Child Health Research Unit (CHRU), Birmingham
Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington D.C.
Washington University School of Medicine in St. Louis - Center for Clinical Studies, St Louis
Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease, Manhasset
University of Rochester Medical Center, Rochester
Carolinas Medical Center - Pediatrics - Infectious Diseases, Charlotte
Nationwide Children's Hospital - Neonatology - Center for Perinatal Research, Columbus
Rhode Island Hospital - Pediatrics, Providence
Bristol Royal Hospital for Children - Paediatric Immunology, Bristol
Saint George's Hospital - Pediatric Infectious Diseases, London
Great Ormond Street Hospital - Infectious Diseases, London
Birmingham Heartlands Hospital, Birmingham
Pennine Acute Hospitals NHS Trust, North Manchester General Hospital - Children's and Adolescent Services, Crumpsall
John Radcliffe Hospital - Children's Hospital - Paediatric Infectious Disease and Immunology, Headington, Oxford
The Great North Children's Hospital - Paediatric Immunology, Newcastle upon Tyne
Sheffield Children's Hospital - Immunology, Sheffield
Southampton Children's Hospital - Allergy, Immunology and Infection, Southampton, Hampshire
National Institute of Allergy and Infectious Diseases (NIAID)
NIH